Great Panther Mining (OTC:GPLDF) Stock, Quote.Headers.trade-ideas

Great Panther Mining Ltd is a precious metals mining and exploration company. The company operates three mines, including the Tucano Gold Mine in Amapa State, Brazil, and two primary silver mines in Mexico: the Guanajuato Mine Complex (GMC) and the Topia Mine. Its Coricancha segment contains the net assets associated with Coricancha and the Corporate segment provides financial, human resources, and technical support to the three mining operations and Coricancha. The GMC operation produces silver and gold in concentrate, and the Topia operation produces silver, gold, lead, and zinc in concentrate for refining off-site. The Tucano operation produces gold dore. It generates the majority of its revenue from Brazil.

GREAT PANTHER MINING LTD by Great Panther Mining Limited

Great Panther Mining Ltd

Zenvia Customer Cloud is the result of innovation and integration of acquisitions that position
Zenvia as one of the leading SaaS providers for customer experience
SÃO PAULO, Jan. 13, 2025 /PRNewswire/ -- Zenvia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) (the "Company"), one of the leading SaaS providers for customer experience (CX) in Latin America, announces the beginning of its new strategic cycle.
Since its inception 21 years ago, Zenvia's mission has always been to revolutionize the experience customers have with companies and brands, and with each new strategic cycle, the Company continues to expand its vision. The launch of Zenvia Customer Cloud in 2024 marks the end of the Company's latest strategic cycle, which began in 2018 and aimed to expand its CX SaaS portfolio by combining investments in M&amp;A and R&amp;D, making Zenvia one of the segment leaders in Latin America. From January 2025, the Company will begin its new strategic cycle, focused on accelerating the growth of Zenvia Customer Cloud - our new core business and our most complete unified customer experience solution.
Zenvia Customer Cloud is a solution that integrates all stages of the customer journey—attract, convert, serve, and nurture—personalizing every interaction from the first contact to post-sales service with extensive use of Artificial Intelligence (AI) tools. With an innovative business model enabling flexible adoption, organizations can easily begin and progressively expand their use of the software, providing Zenvia with what we believe to be a highly scalable revenue growth stream.
Zenvia Customer Cloud is the result of the deep integration of the Company's CX SaaS tools, resulting in a totally unified solution for the customer. Launched in 2024 and leveraged by Product Led Growth (PLG) strategies and international expansion, Zenvia Customer Cloud was already used by 5,700 companies, 20% of which were international customers, and we estimate it generated revenue between R$180 million and R$200 million in the year ended December 31, 2024. We estimate that this operation will grow between 25% and 30% in 2025, with a gross margin of between 68% and 70% and a positive EBITDA margin.

News

ZENV

Zenvia Launches Zenvia Customer Cloud, Aiming For 25%-30% Growth With New Strategic Cycle; 2024 Revenues Estimated Between R$180 Million-R$200 Million From 5.7K Companies; 20% International Clients; Gross Margin 68%-70%

ANGI

IAC To Spin Off Angi,

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>). Here&#8217;s <a href="https://www.benzinga.com//node/42936564">what you need to know.</a>
What To Know: Biohaven and Merus will to co-develop three antibody-based therapies, utilizing Merus&#8217; Biclonics platform alongside its own technologies. The collaboration includes two existing Merus programs and one in early research. 
Under the agreement, Merus will receive an upfront payment and a licensing fee once the first antibody drug conjugate (ADC) candidate is selected. In addition, Merus will cover the costs of preclinical antibody development, while Biohaven will manage the preclinical ADC development expenses. 
If any therapies progress to commercialization, the companies plan to share development costs jointly.
&#8220;We believe this collaboration with Merus will accelerate our ability to create highly differentiated multispecific ADCs, leveraging Biohaven&#8217;s innovative conjugation and payload technologies to deliver optimized ADCs with the potential to significantly benefit patients across various cancer types through an enhanced efficacy and safety profile,&#8221; added Brian Lestini, President, Oncology of Biohaven.
Related Link: <a href="https://www.benzinga.com/general/travel/25/01/42958773/united-airlines-earnings-preview-could-airline-impress-investors-after-deltas-strong-guidance">United Airlines Earnings Preview: Could Airline Impress Investors After Delta&#8217;s Strong Guidance?</a>
MRUS Price Action: Merus stock closed 7.75% lower on Monday at $40.45, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Photo: Shutterstock

Movers

BHVN

MRUS

What's Going On With Merus Stock Monday?

Plains All American Pipeline Have Priced An Underwritten Public Offering Of $1 Billion Aggregate Principal Amount Of 5.950% Senior Unsecured Notes Due 2035 At A Price To The Public of 99.761% Of Their Face Value

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT.
<ul>
<li>For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.</li>
<li>Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the Company's previously announced guidance of a low-single digit percent decline.</li>
</ul>

Guidance

Danaher CEO Says "For Q4 2024, Estimated Revenues Are Anticipated To Increase In The Low-Single Digit Percent Range YoY; Estimated Non-GAAP Core Revenue For Q4 2024 Is Expected To Be Essentially Flat YoY, Which Would Be Above The Company's Previously Announced Guidance Of A Low-Single Digit Percent Decline"

The Company expects to consider a broad range of potential opportunities, including, among others, a sale of the Company, a merger with another strategic partner, a recapitalization or continued execution of the Company's attractive long-term business plan.

SANW

S&W Seed Company Commences Process To Explore And Evaluate Various Strategic Alternatives

DHI Group Announces Restructuring Of Its Operations To Separate The Dice And ClearanceJobs Businesses; 8% Workforce Reduction, Sees $2.2M In Cash Charges, Expects Annual Cost Savings $4M-$6M

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) today announced that it has acquired certain assets within Carter Day International, Inc.'s petrochemical division. The acquired assets now become part of the MAAG business unit within Dover's Pumps &amp; Process Solutions segment, expanding MAAG's pelletizing-system portfolio of dewatering and drying equipment for the plastics industry with highly-engineered products and proprietary technologies, and also include complementary high-volume dryer technology to MAAG's existing portfolio.

Dover Acquires Dryer Manufacturer Technology For The Global Processing Industry; Terms Of The Transaction Were Not Disclosed

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 7.96% on an annualized basis producing an average annual return of 19.36%. Currently, Alnylam Pharmaceuticals has a market capitalization of $33.31 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 15 years ago, it would be worth $14,221.92 today based on a price of $258.27 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736802908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ALNY

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Non-GAAP income from operations in the range of $3.0 million to $4.0 million2.
<ul>
<li>Non-GAAP income from operations in the range of $3.0 million to $4.0 million2.</li>
</ul>

TTAN

ServiceTitan Expects Q4 Total Revenue Of $199M - $201M (Est $222.549M), FY25 Total Revenue Of $761.6M - $763.6M (Est $755.722M)

ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. The company reported quarterly sales of $199.28 million which beat the analyst consensus estimate of $198.52 million by 0.38 percent.

Earnings

Earnings Beats

ServiceTitan Q3 2025 Adj EPS $(0.03), Inline

The $183 million project modernizes campus infrastructure with cost-saving measures, integrates renewable energy generation, and advances decarbonization efforts.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fameresco.com%2F&amp;esheet=54178926&amp;newsitemid=20250113728425&amp;lan=en-US&amp;anchor=Ameresco%2C+Inc.&amp;index=1&amp;md5=b444fa2e971641e38ce9bfbdbd770bfa">Ameresco, Inc.</a>, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), a leading cleantech integrator specializing in energy efficiency and renewable energy, today announced the execution of an Energy Savings Performance Contract (ESPC) with the U.S. General Services Administration (GSA) that will move the Denver Federal Center (DFC) a long way toward GSA's ambitious goal of achieving a net-zero campus by 2045.
The $183 million award will advance the electrification of the DFC with 14.4 megawatts of ground-mount (MW) solar photovoltaic systems and 62.4 million British thermal units per hour (MMBtu/h) of geothermal bores, alongside 20.1 MMBtu/h of electric heat pump capacity. These upgrades are designed to provide year-round heating and cooling to displace fossil fuel-fired equipment across 13 buildings. Additionally, an Energy Sales Agreement within the broader ESPC will leverage tax credits for renewable energy. With approximately half of the campus electricity generated by solar photovoltaics, the project is designed to cut grid-purchased energy use approximately by 51% and reduce fossil fuel consumption by 51.5%.

Contracts

AMRC

Ameresco Awarded $183M Contract To Deliver Energy Resiliency And Net-Zero Solutions At U.S. General Services Administration's Denver Federal Center

WIIM

KB Home shares are trading higher following better-than-expected Q4 financial results.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2024:
<ul>
<li>266,868 DBV Technologies shares,</li>
<li>€ 106,930.51.</li>
</ul>
When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
<ul>
<li>41,159 DBV Technologies shares,</li>
<li>€ 432,367.25.</li>
</ul>
Over the period from July 1, 2024, to December 31, 2024, the following transactions were executed:
<ul>
<li>1682 buy transactions,</li>
<li>1800 sales transactions.</li>
</ul>
Over this same period, the volumes traded represented:
<ul>
<li>404,081 shares and € 296,390.97 on purchases,</li>
<li>440,957 shares and € 340,906.76 on sales.</li>
</ul>

DBVT

DBV Technologies Reports H2 Liquidity Contract Update: 267K Shares, €107K In Account; 1,682 Buy And 1,800 Sales Transactions Covering 404K Shares Purchased, €296K And 441K Shares Sold, €341K

AVAV

AeroVironment Awarded Its Second Delivery Order Totaling $55.3M Of Switchblade Loitering Munition Systems As Part Of U.S. Army's Directed Requirement Lethal Unmanned Systems

KB Home Sees FY25 Housing Revenues $7.00B-$7.50B, Sees FY25 average selling price $488K-$498K

Mezvinsky Will Succeed Sabir Sami
Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) today announced the promotion of Scott Mezvinsky, 49, to KFC Division Chief Executive Officer, reporting to Yum! Brands Chief Executive Officer David Gibbs, effective March 1, 2025. Mezvinsky, a 20-year veteran of the Company who currently serves as President of Taco Bell North America and International, will succeed Sabir Sami, who is stepping down as KFC CEO at the end of February 2025. Mezvinsky will assume global responsibility for driving the brand strategy and performance of KFC.

Management

Scott Mezvinsky Promoted To KFC Division CEO, Effective March 1, 2025; Mezvinsky Will Succeed Sabir Sami

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) reported quarterly earnings of $2.52 per share which beat the analyst consensus estimate of $2.39 by 5.44 percent. The company reported quarterly sales of $2.000 billion which beat the analyst consensus estimate of $1.987 billion by 0.63 percent. This is a 19.47 percent increase over sales of $1.674 billion the same period last year.

KB Home Q4 2024 GAAP EPS $2.52 Beats $2.39 Estimate, Sales $2.000B Beat $1.987B Estimate

AEHR

Aehr Test Systems shares are trading lower after the company reported worse-than-expected Q2 financial results.

Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) reported its Q2 earnings results on Monday, January 13, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Aehr Test System missed estimated earnings by -50.0%, reporting an EPS of $0.02 versus an estimate of $0.04.
Revenue was down $7.98 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company beat on EPS by $0.05 in the previous quarter, leading to a 20.0% increase share price change the next day.
Here's a look at Aehr Test System's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>0.10</td>
<td>-0.03</td>
<td>0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.84</td>
<td>-0.03</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>12.17M</td>
<td>15.44M</td>
<td>7.61M</td>
<td>20.89M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>13.12M</td>
<td>16.60M</td>
<td>7.56M</td>
<td>21.43M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Aehr Test System <a href="https://www.benzinga.com/quote/AEHR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Great Panther Mining

Great Panther Mining (GPLDF) Forecast

Great Panther Mining (OTC:GPLDF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga